Jurgens MS, Safy-Khan M, de Hair MJH, et al. - This study was undertaken to investigate multi-biomarker disease activity (MBDA) blood test objectively measures rheumatoid arthritis (RA) disease activity with a score of 1–100. In CAMERA-II, response profiles of the MBDA score, its individual biomarkers, and DAS28. Researchers assessed a total of 92 patients from CAMERA-II of whom clinical data and serum for MBDA testing at baseline and ≥ 1 time-point from months 1, 2, 3, 4, 5, 6, 9, or 12 were available. The results exhibited that MBDA tracked treatment response in CAMERA-II similarly to DAS28. It was indicated that compared with methotrexate placebo, more individual MBDA biomarkers tracked treatment response to methotrexate with prednisone. In addition, four response profiles could be found.